About-cancer/treatment/clinical-trials/disease/melanoma/treatment
Kho Tej Chaw Kho Mob rau Melanoma
Cov chaw kuaj mob yog cov kev tshawb fawb tshawb fawb uas cuam tshuam nrog tib neeg. Kev kuaj mob hauv cov npe no yog kho tus mob melanoma. Txhua qhov kev sim ntawm daim npe tau txhawb los ntawm NCI.
NCI cov ncauj lus tseem ceeb txog kev sim kho mob piav qhia txog ntau hom thiab ncua sij hawm ntawm kev sim thiab seb lawv raug coj los ua li cas. Cov chaw soj ntsuam kuaj xyuas txoj hauv kev tshiab los tiv thaiv, kuaj pom, lossis kho kab mob. Tej zaum koj yuav xav xav txog kev koom tes hauv kev sim tshuaj kuaj mob. Tham nrog koj tus kws kho mob kom pab txiav txim siab yog tias ib qho zoo rau koj.
Kev Txom Nyem 1-25 ntawm 260 1 2 3 ... 11 Tom ntej>
Lub Hom Phiaj Kho Tau Coj Los ntawm Kev Tshuaj Ntsuam Hauv Kev Kho Mob rau Cov Neeg Mob Nrog Lub Pob Qij Qib Pob Qij Qib, Tawv Qog, lossis Ntau Myeloma (Kev Ntsuam Xyuas MATCH)
Theem II MATCH cov kev sim no yuav kho tau zoo npaum li cas uas yog qhia los ntawm kev tshuaj ntsuam caj ces ua haujlwm rau cov neeg mob qog lossis cov qog ntshav tau nce raws li tsawg kawg ib kab ntawm kev kho mob lossis uas tsis muaj kev pom zoo raws li txoj kev kho tau. Kev tshuaj ntsuam caj ces saib cov cim caj ces (cov caj ces) ntawm cov neeg mob lub qog ua hlav. Cov neeg mob uas muaj caj ces txawv txav (xws li kev sib hloov, ntxiv suab, lossis txav chaw) yuav tau txais txiaj ntsig ntau dua los ntawm kev kho mob uas lub hom phiaj lawv lub qog tshwj xeeb hauv kev mob caj ces. Txheeb xyuas cov kev mob caj ceg no ua ntej yuav pab cov kws kho mob npaj kho zoo dua rau cov neeg mob qog ua hlav, cov qog ntshav, lossis ntau yam mob myeloma.
Qhov chaw: 1189 qhov chaw
Pembrolizumab hauv Kev Kho Mob rau Cov Neeg Mob Hlwb III-IV Siab Mob Melanoma Ua Ntej thiab Tom Qab Kev phais
Kev sim qib II no kawm paub txog pembrolizumab ua haujlwm li cas ua ntej thiab tom qab phais mob hauv kev kho mob rau cov neeg mob theem III-IV siab yuav mob melanoma. Kev txhaj tshuaj tiv thaiv kab mob nrog monoclonal tiv thaiv kab mob, xws li pembrolizumab, tuaj yeem pab lub cev tiv thaiv kab mob hauv lub cev tua cov kabmob, thiab yuav cuam tshuam lub peev xwm ntawm cov qog ua kom loj hlob thiab kis tau. Muab pembrolizumab ua ntej thiab tom qab kev phais mob yuav ua haujlwm zoo dua rau kev kho tus mob melanoma.
Qhov chaw: 709 qhov chaw
Dabrafenib thiab Trametinib Taug qab los ntawm Ipilimumab thiab Nivolumab lossis Ipilimumab thiab Nivolumab Ua raws li Dabrafenib thiab Trametinib hauv Kev Kho Mob rau Cov Neeg Mob Nrog Ntu III-IV BRAFV600 Melanoma
Qhov kev sim rau qib III sim no yuav ua li cas pib kho mob nrog ipilimumab thiab nivolumab ua raws li dabrafenib thiab trametinib ua haujlwm thiab muab piv rau kev kho mob thawj zaug nrog dabrafenib thiab trametinib ua raws li ipilimumab thiab nivolumab hauv kev kho cov neeg mob theem III-IV melanoma uas muaj kev hloov pauv hu ua BRAFV600 thiab tsis tuaj yeem raug tshem tawm los ntawm kev phais mob (tsis tuaj yeem tiv thaiv). Kev txhaj tshuaj tiv thaiv kab mob nrog monoclonal tiv thaiv kab mob, xws li ipilimumab thiab nivolumab, tuaj yeem pab lub cev tiv thaiv kab mob tua cov kab mob qog nqaij hlav, thiab yuav cuam tshuam lub peev xwm ntawm cov qog ntshav kom loj hlob thiab kis tau. Dabrafenib thiab trametinib tuaj yeem thaiv qog kev loj hlob los ntawm kev ua kom muaj lub hom phiaj BRAFV600.
Qhov chaw: 712 qhov chaw
Ipilimumab nrog lossis tsis Nivolumab hauv Kev Kho Tus Neeg Mob Melanoma Uas Yog Ntu IV lossis Theem III thiab tsis tuaj yeem raug tshem tawm los ntawm Kev Kho Mob
Kev sim qib II no tshawb xyuas seb ipilimumab muaj lossis tsis muaj nivolumab ua haujlwm rau kev kho cov neeg mob melanoma uas yog theem IV lossis theem III thiab tsis tuaj yeem raug tshem tawm los ntawm kev phais mob. Kev txhaj tshuaj tiv thaiv kab mob nrog monoclonal tiv thaiv kab mob, xws li ipilimumab thiab nivolumab, tuaj yeem pab lub cev tiv thaiv kab mob tua cov kab mob qog nqaij hlav, thiab yuav cuam tshuam lub peev xwm ntawm cov qog ntshav kom loj hlob thiab kis tau.
Qhov chaw: 600 thaj chaw
Pembrolizumab hauv Kev Kho Tus Neeg Mob nrog Desmoplastic Melanoma Uas Tuaj yeem lossis Kho Mob Tsis Tau
Qhov kev sim theem II no tshawb txog seb pembrolizumab ua haujlwm zoo li cas rau kev kho cov neeg mob desmoplastic melanoma (DM) uas tuaj yeem lossis tshem tawm tsis tau los ntawm kev phais mob (tshawb tsis tau). Cov tshuaj tiv thaiv monoclonal, zoo li pembrolizumab, tuaj yeem thaiv cov protein tshwj xeeb uas yuav ntxiv dag zog rau kev tiv thaiv kab mob thiab tswj qog hlav.
Qhov chaw: 202 thaj chaw
Kev Tshawb Fawb Lub Pob Tawb ntawm Entrectinib (RXDX-101) rau Kev Kho Mob ntawm Cov Neeg Mob Nrog Cov Khoom Siv Hnyav Hleb NTRK 1/2/3 (Trk A / B / C), ROS1, lossis ALK Cov Kev Tsim Kho (Fusions)
Qhov no yog qhib-daim ntawv lo cim, ntau tus neeg, thoob ntiaj teb Phase 2 pob tawb kawm ntawm entrectinib (RXDX-101) rau kev kho mob ntawm cov neeg mob uas muaj cov qog laus uas muaj qhov NTRK1 / 2/3, ROS1, lossis ALK gene fusion. Cov neeg mob yuav muab tso rau cov pob tawb sib txawv raws li hom qog thiab noob fusion.
Qhov chaw: 26 thaj chaw
Kev Nyab Xeeb thiab Ua Tau Zoo ntawm Pembrolizumab Piv rau cov placebo hauv Tshuaj tiv thaiv Qib Siab Txoj Kev Theem II Melanoma (MK-3475-716 / KEYNOTE-716)
Kev tshawb nrhiav 2-ntu no yuav ntsuas qhov kev nyab xeeb thiab kev ua tau zoo ntawm pembrolizumab (MK-3475) piv rau cov placebo hauv cov neeg koom nrog kev phais mob rov qab qhov pheej hmoo siab nyob rau qib II melanoma. Cov neeg koom nrog hauv Tshooj 1 yuav tau txais pembrolizumab lossis placebo hauv qhov tsim ob qhov muag tsis pom kev zoo txog li 17 mus. Cov neeg koom nrog tau txais cov placebo lossis uas tsis kho mob tom qab tau txais 17 lub sijhawm ntawm pembrolizumab hauv Ntu 1, tsis muaj kev mob rov qab los ntawm 6 lub hlis tom qab ua tiav pembrolizumab hauv Tshooj 1, thiab tsis nres kho mob nrog pembrolizumab rau kev rov mob lossis tsis nkag siab, tej zaum yuav tsim nyog tau txais txog 35 lub sijhawm ntxiv ntawm pembrolizumab hauv Tshooj 2 hauv kev qhib tsim daim ntawv lo. Qhov kev xav ua ntej ntawm txoj kev tshawb no yog pembrolizumab tsub kom rov muaj sia nyob ntev (RFS) piv rau cov placebo.
Qhov chaw: 25 thaj chaw
Nivolumab nrog lossis tsis siv Ipilimumab hauv Kev Kho Cov Neeg Mob Hluas Dua nrog Mob Rov Ntshav Rov Qab lossis Cov Pob Qij Tawv Los yog Sarcomas
Theem I / II kev sim no kawm txog cov kev mob tshwm sim thiab qhov zoo tshaj plaws ntawm nivolumab thaum muab nrog lossis tsis muaj ipilimumab kom pom tias lawv ua haujlwm zoo npaum li cas rau kev kho cov neeg mob qog nqaij hlav tawv lossis tawv nqaij uas rov qab tshwm sim (ib qho dua) lossis tsis teb rau kev kho refractory). Kev txhaj tshuaj tiv thaiv kab mob nrog monoclonal tiv thaiv kab mob, xws li nivolumab thiab ipilimumab, tuaj yeem pab lub cev tiv thaiv kab mob tua lub qog ntshav, thiab yuav cuam tshuam lub peev xwm ntawm cov qog ntshav kom loj hlob thiab kis tau. Nws tseem tsis tau paub meej tias nivolumab ua haujlwm zoo dua nyob ib leeg lossis nrog ipilimumab hauv kev kho cov neeg mob uas rov ua dua li lossis cov nqaij hlav tawv lossis cov pob zeb tawv.
Qhov chaw: 24 thaj chaw
Kev Tshawb Fawb thiab Kev Tshawb Xyuas Kev Tshawb Fawb thiab Cohort Qhov Kev Tshawb Fawb Qhia Txog NKTR-214 hauv Kev Sib Daws Nrog Nivolumab thiab Lwm Yam Kev Kho Mob Qog Plaub Hau hauv Cov Neeg Mob Nrog Xaiv Advanced Tumors (PIVOT-02)
Hauv plaub qhov kev tshawb fawb no, NKTR-214 yuav raug tswj hwm nrog nivolumab hauv Ntu 1, hauv kev sib xyaw nrog nivolumab nrog lossis tsis muaj tshuaj kho mob ntau yam hauv Ntu 2, thiab nrog nivolumab thiab ipilimumab hauv Ntu 3 & 4. Hauv Ntu 1, Pom zoo Theem 2 Koob Tshuaj (RP2D) ntawm NKTR-214 nrog nivolumab yuav raug txiav txim siab. Hauv Ntu 2, NKTR-214 nrog nivolumab ntawm RP2D yuav raug soj ntsuam raws li kev kho mob thib ib thiab / lossis raws li txoj kev kho thib ob lossis thib peb hauv kev xaiv cov neeg mob uas muaj Melanoma, Renal Cell Carcinoma (RCC), Tsis Mob Ntshav Tsis Muaj Ntshav Cell (NSCLC) ), Urothelial Carcinoma (UC), metastatic Cancer mis (mBC) thiab Khees Xaws Mob Qog Qog (CRC). Tsis tas li ntawd, hauv Tshooj 2, RP2D ntawm NKTR-214 nrog nivolumab thiab ntau yam tshuaj tua kab mob thiab kev kho mob rau hauv kev xaiv cov pawg neeg mob ntawm NSCLC cov neeg mob yuav raug txiav txim siab. Hauv Tshooj 3, ob peb lub cev sib txawv ntawm cov kev sib txuas ua ke ntawm NKTR-214 ntxiv rau nivolumab thiab ipilimumab yuav raug tshuaj xyuas hauv cov neeg mob xaiv nrog RCC, NSCLC, Melanoma, thiab UC. Hauv Tshooj 4, kev nyab xeeb thiab kev ua tau zoo ntawm kev sib koom ua ke yuav raug txheeb xyuas ntxiv hauv kev xaiv cov neeg mob RCC, NSCLC, Melanoma thiab UC.
Qhov chaw: 22 thaj chaw
Theem 1 / 1b Kev Tshawb Fawb txhawm rau Kev Ntsuas Kev Nyab Xeeb thiab Kev Nyuaj Siab ntawm CPI-444 Ib leeg thiab ua ke nrog Atezolizumab hauv Kheesxawj Qib Siab
Qhov no yog theem 1 / 1b qhib-daim ntawv lo, multicenter, koob tshuaj xaiv-kawm ntawm CPI-444, lub qhov ncauj me me ntawm lub molecule tsom mus rau adenosine-A2A receptor ntawm T-lymphocytes thiab lwm cov hlwb ntawm cov tshuaj tiv thaiv. Qhov kev sim siab no yuav kawm txog kev nyab xeeb, tiv taus thiab tawm tsam qog ntawm CPI-444 ua ib tus neeg sawv cev nkaus xwb thiab ua ke nrog kev noj zaub mov noj, PD-L1 inhibitor tiv thaiv ntau cov qog hlav. CPI-444 thaiv adenosine los ntawm khi rau A2A receptor. Adenosine tswj kev tiv thaiv cov qog ua haujlwm ntawm T cell thiab lwm cov kab mob tiv thaiv.
Qhov chaw: 22 thaj chaw
Kev Tshawb Fawb txog Pembrolizumab (MK-3475) hauv Cov Neeg Koom Tes Nrog Tus Txheej Txheem Tshaj Tawm Tumor lossis Lymphoma (MK-3475-051 / KEYNOTE-051)
Qhov no yog ob feem ntawm kev tshawb nrhiav pembrolizumab (MK-3475) hauv cov kws kho mob hauv cov menyuam yaus uas muaj qee yam mob qog nqaij hlav hauv qab no: - tus mob siab ntsws nyuaj siab (6 lub hlis txog rau 18 xyoo rov hauv), - nce siab, rov mob lossis rov ua kom zoo dua cov kev tuag. ligand 1 (PD-L1)-cov kab mob qog ua mob qog ua pob lossis lwm yam mob qog nqaij hlav (6 lub hlis txog 18 xyoo), - rov mob lossis rov kho dua qub Hodgkin lymphoma (rrcHL) (3 xyoos txog rau 18 xyoo), lossis - nce siab rov mob lossis rov ua dua microsatellite-instability-siab (MSI-H) cov qog ua haujlwm (6 lub hlis txog 18 xyoo). Ntu 1 yuav pom cov koob tshuaj siab tshaj plaws (MTD) / kev siv tshuaj ntau tshaj plaws (MAD), paub meej cov koob tshuaj, thiab nrhiav pom qhov Theem 2 koob tshuaj (RP2D) rau kev kho mob pembrolizumab. Ntu 2 tseem yuav ntsuas ntxiv txog kev nyab xeeb thiab kev ua tau zoo ntawm kev kuaj xyuas menyuam yaus RP2D. Qhov kev xav ua ntej ntawm txoj kev tshawb no yog qhov tso ntshav (paum) rau cov menyuam pembrolizumab rau cov menyuam muaj mob melanoma siab heev; PD-L1 zoo heev, rov ua dua lossis refractory cov qog lossis lwm yam mob qog nqaij hlav; nce siab, rov ua dua lossis refractory MSI-H khoom qog ua haujlwm; lossis rrcHL, yuav ua rau Cov Lus Teb Lub Hom Phiaj (ORR) ntau dua 10% rau tsawg kawg ib ntawm cov hom mob qog nqaij hlav. Nrog Kev Hloov Kho 8, kev sau npe ntawm cov neeg koom nrog cov qog thiab cov neeg tuaj koom hnub nyoog 6 lub hlis txog 12 xyoos nrog mob qog nqaij hlav kaw. Kev cuv npe ntawm cov neeg koom hnub nyoog ≥12 xyoos txog ≤18 xyoo nrog txiv ntsej rag txuas ntxiv. Cuv npe ntawm cov neeg koom nrog MSI-H cov qog hlav tseem yuav txuas ntxiv. rov mob los yog rov refractory MSI-H khoom hlav; lossis rrcHL, yuav ua rau Cov Lus Teb Lub Hom Phiaj (ORR) ntau dua 10% rau tsawg kawg ib ntawm cov hom mob qog nqaij hlav. Nrog Kev Hloov Kho 8, kev sau npe ntawm cov neeg koom nrog cov qog thiab cov neeg tuaj koom hnub nyoog 6 lub hlis txog 12 xyoos nrog mob qog nqaij hlav kaw. Kev cuv npe ntawm cov neeg koom hnub nyoog ≥12 xyoos txog ≤18 xyoo nrog txiv ntsej rag txuas ntxiv. Cuv npe ntawm cov neeg koom nrog MSI-H cov qog hlav tseem yuav txuas ntxiv. rov mob los yog rov refractory MSI-H khoom hlav; lossis rrcHL, yuav ua rau Lub Hom Phiaj Lus Teb (ORR) ntau dua 10% rau tsawg kawg ib ntawm cov hom mob qog nqaij hlav. Nrog Kev Hloov Kho 8, kev sau npe ntawm cov neeg koom nrog cov qog thiab cov neeg koom ua si hnub nyoog 6 hlis txog rau 12 xyoo nrog mob qog nqaij hlav kaw. Kev cuv npe ntawm cov neeg koom hnub nyoog ≥12 xyoo mus rau years18 xyoo nrog mob qog mis txuas ntxiv mus. Cuv npe ntawm cov neeg koom nrog MSI-H cov qog hlav tseem yuav txuas ntxiv.
Qhov chaw: 19 thaj chaw
Kev Nyab Xeeb thiab Kev Ua Tau Zoo ntawm IMCgp100 Versus Tus Kws Tshawb Xyuas Xaiv hauv Advanced Uveal Melanoma
Txheeb xyuas txhua qhov muaj sia nyob ntawm HLA-A * 0201 zoo tus neeg laus cov neeg mob uas tsis tau txais kev kho dua UM tau txais IMCgp100 piv rau Tus Kws Tshawb Fawb Xaiv ntawm dacarbazine, ipilimumab, lossis pembrolizumab.
Qhov chaw: 18 thaj chaw
Enapotamab Vedotin (HuMax-AXL-ADC) Kev Nyab Xeeb Kev Nyab Xeeb Hauv Cov Neeg Mob Nrog Cov Qog Ua Si
Lub hom phiaj ntawm kev sim no yog txiav txim siab qhov ntau tshaj plaws zam lub koob tshuaj thiab tsim kom muaj kev nyab xeeb ntawm HuMax-AXL-ADC hauv cov pej xeem sib xyaw ntawm cov neeg mob uas tau teev tseg cov qog.
Qhov chaw: 18 thaj chaw
Kev Tshawb Fawb Txog XmAb®20717 Hauv Cov Ntsiab Lus Nrog Xaiv Qiv Cov Pob Qij Qib Dua
Qhov no yog Ntu 1, ntau koob tshuaj, nce ntxiv koob tshuaj tiv thaiv kev kawm tshawb xyuas los txhais lub MTD / RD thiab kev tswj hwm ntawm XmAb20717, kom piav qhia txog kev nyab xeeb thiab tiv taus, soj ntsuam PK thiab tshuaj tiv thaiv kab mob, thiab ntsuas ua ntej ntsuas cov qog ua haujlwm ntawm XmAb20717 hauv cov ncauj lus nrog xaiv paub ntau yam khoom hlav.
Qhov chaw: 15 thaj chaw
Talimogene Laherparepvec thiab Pembrolizumab hauv Kev Kho Cov Neeg Mob Theem III-IV Melanoma
Kev sim qib II no tshawb xyuas seb zoo li talimogene laherparepvec thiab pembrolizumab ua haujlwm rau kev kho cov neeg mob theem melanoma III-IV. Kev siv roj ntsha, xws li talimogene laherparepvec, siv cov tshuaj uas tsim los ntawm cov kab mob muaj sia uas tuaj yeem txhawb lossis tiv thaiv kom tsis muaj zog tiv thaiv kev tiv thaiv kab mob sib txawv thiab txwv tsis pub cov qog ua kom loj hlob tuaj. Kev txhaj tshuaj tiv thaiv kab mob nrog monoclonal tiv thaiv kab mob, xws li pembrolizumab, tuaj yeem pab lub cev tiv thaiv kab mob hauv lub cev tua cov kabmob, thiab yuav cuam tshuam lub peev xwm ntawm cov qog ua kom loj hlob thiab kis tau. Muab cov tshuaj talimogene laherparepvec thiab pembrolizumab tuaj yeem ua haujlwm zoo dua rau kev kho cov neeg mob melanoma los ntawm kev ua kom cov qog.
Qhov chaw: 16 thaj chaw
Dabrafenib, Trametinib, thiab Navitoclax hauv Kev Kho Mob Rau Cov Neeg Mob nrog BRAF Mutant Melanoma lossis Cov Tawv Rog Pob Txha uas yog Metastatic lossis tsis tuaj yeem raug tshem tawm los ntawm Kev Kho Mob
Theem I / II kev sim no kawm txog kev phiv thiab koob tshuaj zoorafenib, trametinib, thiab navitoclax thiab kom pom tias lawv ua haujlwm zoo npaum li cas rau kev kho cov neeg mob BRAF mutant melanoma lossis cov qog uas tau kis mus rau lwm qhov ntawm lub cev lossis tsis tuaj yeem tshem tawm los ntawm kev phais mob. Dabrafenib, trametinib, thiab navitoclax tuaj yeem txwv kev loj hlob ntawm cov qog ntshav los ntawm kev thaiv qee cov enzymes xav tau rau kev loj hlob ntawm tes.
Qhov chaw: 24 thaj chaw
Kev Tshawb Fawb Ntawm Avelumab Hauv Kev Sib Tw Nrog Lwm Yam Tshuaj Tiv Thaiv Kab Mob hauv Cov Kws Kho Mob Tshaj Plaws hauv Kev Kho Mob Malignancies (JAVELIN Medley)
Qhov no yog Ntu 1b / 2 koob-kawm txog kev ua kom zoo los soj ntsuam kev nyab xeeb, pharmacokinetics, pharmacodynamics, thiab cov haujlwm ua ntej antitumor ntawm avelumab (MSB0010718C) ua ke nrog lwm cov tshuaj tiv thaiv qog noj ntshav hauv cov neeg mob uas muaj cov pob qog ntshav hauv cheeb tsam lossis mob ua kom zoo. Lub hom phiaj tseem ceeb yog txhawm rau ntsuas kev nyab xeeb thiab cov cim pib ntawm kev ua tau zoo ntawm ntau yam avelumab sib xyaw nrog lwm cov tshuaj tiv thaiv kabmob kheesxaws, txhim kho kev txhaj tshuaj raws li qhov tsim nyog, hauv cov kev ntsuas tsawg tsawg.
Qhov chaw: 12 thaj chaw
Kev Tshawb Fawb Kev Siv Tshuaj Tiv Thaiv Kev Tshawb Fawb los soj ntsuam qhov kev nyab xeeb, thev taus thiab ua tau zoo ntawm Anti-LAG-3 Nrog thiab tsis muaj qhov tiv thaiv PD-1 hauv Kev Kho Mob Cov Tawv Rog
Lub hom phiaj ntawm txoj kev tshawb no yog txhawm rau soj ntsuam kev nyab xeeb, tiv taus thiab kev ua tau zoo ntawm kev sim tshuaj BMS-986016 muab rau ib leeg thiab kev sib xyaw nrog nivolumab hauv cov neeg mob qog uas tau kis thiab / lossis tsis tuaj yeem tshem tawm los ntawm kev phais mob. Cov qog mob qog hauv qab no muaj nyob rau hauv qhov kev tshawb fawb no: Tsis mob Tawv Qog Mob Ntshav (NSCLC), mob qog nqaij hlav, mob nqaij hlav ntshav siab, mob nqaij hlav hauv hlwb, mob qog nqaij hlav, mob zais zais, mob hlwb ntawm lub taub hau thiab caj dab, thiab melanoma, uas tsis tau dhau los kho nrog kev kho mob. NSCLC thiab melanoma uas tau tau yav tas los kho nrog tshuaj tiv thaiv kab mob.
Qhov chaw: 12 thaj chaw
Kev Nyab Xeeb Kev Nyab Xeeb, Kev Ncaj Ncees thiab PK Kev Kawm ntawm DCC-2618 hauv Cov Neeg Mob Nrog Kev Tshaj Tawm Malignancies
Qhov no yog Ntu 1, qhib-daim ntawv lo, thawj-hauv-tib neeg (FIH) koob tshuaj-kev kawm nce siab los tsim kev tshuaj xyuas txog kev nyab xeeb, kev tiv taus zoo, cov tshuaj pharmacokinetics (PK), pharmacodynamics (PD) thiab kev tiv thaiv ua ntej ntawm kev ua haujlwm ntawm DCC-2618, tswj hwm qhov ncauj (PO), hauv cov neeg laus cov neeg mob uas muaj lub siab phem. Txoj kev tshawb fawb muaj 2 ntu, ntu-nce-nce qib thiab qhov kev nthuav dav.
Qhov chaw: 12 thaj chaw
Kev Tshawb Fawb ntawm NKTR-214 Sib xyaw Nrog Nivolumab vs Nivolumab Ib leeg hauv cov neeg tuaj koom nrog Tsis tau txais kev kho mob uas tsis tau ua lossis Metastatic Melanoma
Lub hom phiaj ntawm txoj kev tshawb no yog txhawm rau ntsuas qhov ua tau zoo (zoo npaum li cas cov tshuaj ua haujlwm), kev nyab xeeb, thiab kev tiv taus ntawm kev tshawb nrhiav tshuaj hu ua NKTR-214, thaum ua ke nrog nivolumab tiv thaiv nivolumab muab ib leeg nyob rau hauv cov neeg koom nrog kev kho tsis mob melanoma tawv nqaij uas yog tsis tuaj yeem raug phais lossis kis tau
Qhov chaw: 10 thaj chaw
Kev Tshawb Fawb ntawm Relatlimab Ntxiv Nivolumab Versus Nivolumab Ib leeg hauv Cov Neeg Koom Nrog Advanced Melanoma
Lub hom phiaj ntawm qhov kev tshawb fawb no yog txiav txim siab seb nivolumab sib xyaw nrog relatlimab ua tau zoo dua li nivolumab los ntawm nws tus kheej hauv kev kho mob tsis tuaj yeem tiv thaiv tus mob melanoma lossis melanoma uas tau sib kis.
Qhov chaw: 13 thaj chaw
Pembrolizumab thiab Ipilimumab hauv Kev Kho Cov Neeg Mob Nrog Kev Kho Mob Ua Ntej Siab Melanoma
Kev sim qib II no tshawb xyuas seb pembrolizumab zoo li cas thiab ipilimumab ua haujlwm rau kev kho cov neeg mob uas muaj mob melanoma uas tau kis mus rau lwm qhov ntawm lub cev. Kev txhaj tshuaj tiv thaiv kab mob nrog monoclonal tiv thaiv kab mob, xws li pembrolizumab thiab ipilimumab, tuaj yeem pab lub cev tiv thaiv kab mob hauv lub cev tua cov kabmob, thiab yuav cuam tshuam lub peev xwm ntawm cov qog ntshav kom loj hlob thiab kis tau.
Qhov chaw: 10 thaj chaw
Cov Kev Tshawb Nrhiav Kev Ntsuam Xyuas ntawm CMP-001 hauv Kev Sib xyaw Nrog Pembrolizumab lossis raws li Kev Tshuaj Kho Mob
Txoj kev kawm no yuav ua ob ntu: Ntu 1 yuav raug siv los ntawm Kev Siv Qhov Ntsuas Kev Tshawb Xyuas thiab nthuav dav. Ntu 1 Kev Nqes Tes Ua Ntu lub sij hawm ntawm qhov kev kawm no yuav qhia txog qhov kev nyab xeeb thiab tiv thaiv kev noj tshuaj kom raug coj los soj ntsuam ntxiv hauv Ntu 1 Kev Tshem Tawm kom nthuav dav. Ntu 2 ntawm qhov kev tshawb fawb no yuav ua rau ntawm Ntu 1 Nto nthuav dav theem thiab yuav ntsuas qhov kev nyab xeeb thiab ua tau zoo ntawm CMP-001 thaum muab rau kev kho mob.
Qhov chaw: 12 thaj chaw
Theem 1b / 2 Kev Sim ntawm Lenvatinib (E7080) Ntxiv rau Pembrolizumab hauv Cov Ntsiab Lus Nrog Cov Khoom Xaiv Cov Tawv Qib
Qhov no yog qhib-qhib Phase 1b / 2 sim ntawm lenvatinib (E7080) ntxiv rau pembrolizumab hauv koom nrog cov qog ua haujlwm uas tau xaiv. Ntu 1b yuav txiav txim siab thiab lees paub qhov siab tshaj plaws siab ntev tshaj plaws koob tshuaj tiv thaiv (MTD) rau lenvatinib ua ke nrog 200 milligrams (mg) (tso ntshav [IV], txhua 3 lub lis piam [Q3W]) pembrolizumab hauv cov neeg koom nrog cov qog ua haujlwm uas tau xaiv (piv txwv li tsis mob me me hauv lub ntsws. mob qog nqaij hlav, lub raum cell carcinoma, endometrial carcinoma, carcinoma urothelial carcinoma, squamous cell carcinoma ntawm lub taub hau thiab caj dab, los yog melanoma) Ntu 2 (Kev nthuav dav) yuav soj ntsuam kev nyab xeeb thiab kev ua haujlwm ntawm kev sib koom ua ke hauv 6 pawg ntawm qhov chaw ntawm MTD los ntawm Ntu 1b (lenvatinib 20 mg / hnub ntawm qhov ncauj + pembrolizumab 200 mg Q3W, IV).
Qhov chaw: 10 thaj chaw
Txoj kev tshawb ntawm Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, hauv Kev Kho Mob ntawm Cov Neeg Mob Nrog Metastatic Melanoma
Lub zeem muag, kev cuam tshuam ntawm cov tub ntxhais kawm ntau ntxiv los soj ntsuam cov kev kho mob ntawm tes (ACT) los ntawm kev lis ntshav ntawm LN-144 (autologous TIL) ua raws li los ntawm interleukin 2 (IL-2) tom qab tsis siv tshuaj tua kab mob lymphodepletion (NMA LD).
Qhov chaw: 13 thaj chaw
1 2 3 ... 11 Ntxiv mus>
